AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16619563 — intervention group
Group type: COMPARATOR
Intervention: 1 KE of OK-432 (arm B)
Number of subjects: 38
Study 14653278 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion
Number of subjects: 10
Study 14653278 — intervention group
Group type: COMPARATOR
Intervention: Conventional rotary handpiece
Number of subjects: 10
Study 8784622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 50
Study 8784622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1617789 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary artery angioplasty (PTCA)
Number of subjects: 15
Study 1617789 — intervention group
Group type: COMPARATOR
Intervention: Conservative medical treatment
Number of subjects: 15
Study 31645229 — intervention group
Group type: EXPERIMENTAL
Intervention: EDVIP (Emergency Department Violence Intervention Program)
Number of subjects: 130
Study 31645229 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 130
Study 30355086 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mechanical thrombectomy (MT)
Number of subjects: 300
Study 30355086 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (including rescue MT after neurological deterioration)
Number of subjects: 300
Study 27197293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (150 min/wk; n = 44)
Number of subjects: 137
Study 27197293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (300 min/wk; n = 48)
Number of subjects: 137
Study 27197293 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintain usual activity levels; n = 45)
Number of subjects: 137
Study 25209445 — intervention group
Group type: EXPERIMENTAL
Intervention: UCMSC transplantation
Number of subjects: 34
Study 25209445 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Number of subjects: 34
Study 25209445 — intervention group
Group type: COMPARATOR
Intervention: Self-healing
Number of subjects: 34
Study 22858449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tobacco cigarette smoking
Number of subjects: 30
Study 22858449 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tobacco cigarette smoking
Number of subjects: 30
Study 22858449 — intervention group
Group type: EXPERIMENTAL
Intervention: Active e-cigarette smoking
Number of subjects: 30
Study 22858449 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive e-cigarette smoking
Number of subjects: 30
Study 22858449 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 30
Study 20117915 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics administered on the first surgical visit, followed by placebo on the second visit after 3 weeks.
Number of subjects: 100
Study 20117915 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered on the first surgical visit, followed by antibiotics on the second visit after 3 weeks.
Number of subjects: 100
Study 18952354 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Emergency Team (MET) system
Number of subjects: 3650
Study 18952354 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 3650
Study 16632329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl-EPA 2g/day
Number of subjects: 84
Study 16632329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 12831411 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5
Number of subjects: 26
Study 12831411 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 26
Study 11055152 — intervention group
Group type: EXPERIMENTAL
Intervention: Honest completion of noncognitive measures
Number of subjects: 0
Study 11055152 — intervention group
Group type: EXPERIMENTAL
Intervention: Faking noncognitive measures
Number of subjects: 0
Study 8781292 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic diabetic patients (IDDM)
Number of subjects: 16
Study 8781292 — intervention group
Group type: COMPARATOR
Intervention: Nonneuropathic diabetic patients (IDDM)
Number of subjects: 16
Study 8781292 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathic diabetic patients (NIDDM)
Number of subjects: 16
Study 8781292 — intervention group
Group type: COMPARATOR
Intervention: Nonneuropathic diabetic patients (NIDDM)
Number of subjects: 16
Study 1478616 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialised venous blood (A Clamp)
Number of subjects: 9
Study 1478616 — intervention group
Group type: COMPARATOR
Intervention: Venous blood (V Clamp)
Number of subjects: 9
Study 6088439 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified concentrated bran product (FiberformR, 3.5 g) three times daily for 6 weeks
Number of subjects: 21
Study 6088439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30886201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercropped with deficient nitrogen (50% N)
Number of subjects: 3
Study 30886201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercropped with adequate nitrogen (100% N)
Number of subjects: 3
Study 30886201 — intervention group
Group type: COMPARATOR
Intervention: Monocropped with deficient nitrogen (50% N)
Number of subjects: 3
Study 30886201 — intervention group
Group type: COMPARATOR
Intervention: Monocropped with adequate nitrogen (100% N)
Number of subjects: 3
Study 30886201 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive nitrogen (150% N)
Number of subjects: 3
Study 28612324 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp messaging (3 times a week for 4 weeks)
Number of subjects: 182
Study 28612324 — intervention group
Group type: COMPARATOR
Intervention: PowerPoint presentation (weekly for 4 weeks)
Number of subjects: 182
Study 26852040 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin inhalation solution (APT-1026) 240mg BID for 28 days
Number of subjects: 330
Study 26852040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 24059674 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D camera
Number of subjects: 24
Study 23281860 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to preselected favorite music for 40 minutes
Number of subjects: 60
Study 23281860 — intervention group
Group type: COMPARATOR
Intervention: Waiting for the operation without music (Control)
Number of subjects: 60
Study 20669632 — intervention group
Group type: EXPERIMENTAL
Intervention: New drugs and targeted therapies for high-risk groups
Number of subjects: 0
Study 20669632 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalated treatment for better-defined low-risk groups
Number of subjects: 0
Study 20669632 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (transfusions, antibiotics, pain control)
Number of subjects: 0
Study 20669632 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized units and clinical research
Number of subjects: 0
Study 18534221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg per day of PEG3350
Number of subjects: 103
Study 18534221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg per day of PEG3350
Number of subjects: 103
Study 18534221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg per day of PEG3350
Number of subjects: 103
Study 18534221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 16104914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 185
Study 16104914 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil
Number of subjects: 185
Study 16104914 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 185
Study 16104914 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin and Naftopidil (both)
Number of subjects: 185
Study 11882400 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (jejunal tube feeding; Survimed OPD; 30 kcal/kg)
Number of subjects: 89
Study 11882400 — intervention group
Group type: EXPERIMENTAL
Intervention: Early jejunal feeding combined with prophylactic imipenem (Tienam, 500 mg intravenously twice each day)
Number of subjects: 89
Study 11882400 — intervention group
Group type: COMPARATOR
Intervention: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%; 30 kcal/kg)
Number of subjects: 89
Study 9932944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug group (low-molecular weight heparinoid)
Number of subjects: 1259
Study 9932944 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 1259
Study 9932944 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of glucose on outcome
Number of subjects: 1259
Study 9932944 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute blood glucose level
Number of subjects: 1259
Study 7503622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg/day
Number of subjects: 241
Study 7503622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 270 mg/day
Number of subjects: 241
Study 7503622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 to 360 mg/day
Number of subjects: 241
Study 7503622 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 241
Study 7503622 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Verapamil 480 mg/day
Number of subjects: 241
Study 2157737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (0.25 x 10(4) PFU)
Number of subjects: 130
Study 2157737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (0.5 x 10(4) PFU)
Number of subjects: 130
Study 2157737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (10(4) PFU)
Number of subjects: 130
Study 2157737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (all doses)
Number of subjects: 130
Study 2157737 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent rotavirus vaccine (medium and high doses)
Number of subjects: 130
Study 6987185 — intervention group
Group type: EXPERIMENTAL
Intervention: Active powder containing undecylenic acid 2% and zinc undecylenate 20%
Number of subjects: 151
Study 6987185 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 151
Study 31852422 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c levels
Number of subjects: 8145
Study 31504106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (1 hour at 70% peak oxygen uptake)
Number of subjects: 24
Study 31504106 — intervention group
Group type: COMPARATOR
Intervention: Control (8 hours rest)
Number of subjects: 24
Study 31504106 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24
Study 28544265 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) early group
Number of subjects: 60
Study 28544265 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) late group
Number of subjects: 60
Study 28544265 — intervention group
Group type: COMPARATOR
Intervention: Business as Usual (BAU)
Number of subjects: 60
Study 25945260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive and physical training (8-week duration)
Number of subjects: 70
Study 25945260 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 70
Study 25945260 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 70
Study 23331949 — intervention group
Group type: EXPERIMENTAL
Intervention: ART48 (48 weeks antiretroviral therapy)
Number of subjects: 30
Study 23331949 — intervention group
Group type: EXPERIMENTAL
Intervention: ART12 (12 weeks antiretroviral therapy)
Number of subjects: 30
Study 23331949 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 30
Study 21216164 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprinomectin (EPM) pour-on preparation at a dose of 0.5 mg/kg bodyweight
Number of subjects: 15
Study 21216164 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 animals)
Number of subjects: 15
Study 19861619 — intervention group
Group type: EXPERIMENTAL
Intervention: rDEN4Delta30‐4995
Number of subjects: 28
Study 19861619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17710670 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises with vagal biofeedback (6 breaths/min, 5 min each day for 4 weeks)
Number of subjects: 40
Study 17710670 — intervention group
Group type: COMPARATOR
Intervention: Control group (received similar information and care)
Number of subjects: 40
Study 15895315 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (CTG)
Number of subjects: 15
Study 15895315 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ETG)
Number of subjects: 15
Study 15895315 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 15
Study 11923161 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days
Number of subjects: 207
Study 11923161 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone applied for seven days
Number of subjects: 207
Study 11923161 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (0.1% betamethasone valerate and 1% hydrocortisone)
Number of subjects: 207
Study 9799030 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (N = 14), treated with 1 mg 17beta‐estradiol once daily and 5 or 10 mg dydrogesterone once daily during the third and fourth week of every 4 weeks
Number of subjects: 29
Study 9799030 — intervention group
Group type: COMPARATOR
Intervention: C-group (N = 15), which did not receive therapy
Number of subjects: 29
Study 8563340 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system
Number of subjects: 0
Study 8563340 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 0
Study 8563340 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2391738 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily
Number of subjects: 178
Study 2391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily
Number of subjects: 178
Study 2391738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg twice daily
Number of subjects: 178
Study 487880 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0
Study 487880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27992833 — intervention group
Group type: COMPARATOR
Intervention: Control (minimal drinking quantity and frequency questions)
Number of subjects: 290
Study 27992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Consequences (College Alcohol Problems Scale; CAPS‐r)
Number of subjects: 290
Study 27992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Norms (Drinking Norms Rating Form)
Number of subjects: 290
Study 27992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic (Alcohol Use Disorders Identification Test)
Number of subjects: 290
Study 27992833 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (all themes)
Number of subjects: 290
Study 26264702 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 100 mg
Number of subjects: 0
Study 26264702 — intervention group
Group type: EXPERIMENTAL
Intervention: Evacetrapib 300 mg
Number of subjects: 0
Study 23824078 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly Adi women
Number of subjects: 531
Study 21679043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac 3.75 mg
Number of subjects: 353
Study 21679043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac 37.5 mg
Number of subjects: 353
Study 21679043 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diclofenac 75 mg
Number of subjects: 353
Study 21679043 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 353
Study 21679043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 19628193 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 100
Study 19628193 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/day)
Number of subjects: 100
Study 19628193 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patients (statin treatments)
Number of subjects: 100
Study 16641127 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea treatment for rhinovirus infection
Number of subjects: 399
Study 16641127 — intervention group
Group type: EXPERIMENTAL
Intervention: WURSS questionnaire
Number of subjects: 399
Study 16641127 — intervention group
Group type: EXPERIMENTAL
Intervention: Jackson questionnaire
Number of subjects: 399
Study 16641127 — intervention group
Group type: EXPERIMENTAL
Intervention: WURSS and Jackson questionnaires
Number of subjects: 399
Study 16641127 — intervention group
Group type: EXPERIMENTAL
Intervention: Wisconsin Upper Respiratory Symptom Survey
Number of subjects: 399
Study 15574077 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydrated state induced by glycerol ingestion
Number of subjects: 8
Study 15574077 — intervention group
Group type: COMPARATOR
Intervention: Control state
Number of subjects: 8
Study 11065035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidotic group (14 infants)
Number of subjects: 92
Study 11065035 — intervention group
Group type: COMPARATOR
Intervention: Control group (78 deliveries)
Number of subjects: 92
Study 11065035 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleated red blood cell counts
Number of subjects: 92
Study 9190237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytograms and tissue sections of nasal polyps and mucosa in patients with allergic rhinitis
Number of subjects: 30
Study 9190237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytograms and tissue sections of nasal polyps and mucosa in patients with nonallergic eosinophilic rhinitis
Number of subjects: 30
Study 9190237 — intervention group
Group type: COMPARATOR
Intervention: Cytograms and biopsies in control group (20 asymptomatic persons)
Number of subjects: 30
Study 1872460 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg)
Number of subjects: 30
Study 1872460 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg)
Number of subjects: 30
Study 1872460 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2 mg/kg)
Number of subjects: 30
Study 6638026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-prescriber group
Number of subjects: 81
Study 6638026 — intervention group
Group type: COMPARATOR
Intervention: Physician-prescriber group
Number of subjects: 81
Study 30712739 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation and Interactive Guided Imagery (PMR-IGI)
Number of subjects: 104
Study 30712739 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 104
Study 28235529 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine plus 2 μg/kg dexmedetomidine, 1 mL/kg
Number of subjects: 60
Study 28235529 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine, 1 mL/kg
Number of subjects: 60
Study 25367012 — intervention group
Group type: EXPERIMENTAL
Intervention: Software reports (SR)
Number of subjects: 111
Study 24203450 — intervention group
Group type: EXPERIMENTAL
Intervention: ZST (1.0 mg)
Number of subjects: 4
Study 24203450 — intervention group
Group type: EXPERIMENTAL
Intervention: ZST (1.75 mg)
Number of subjects: 4
Study 24203450 — intervention group
Group type: EXPERIMENTAL
Intervention: ZST (3.5 mg)
Number of subjects: 4
Study 24203450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 22482874 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 222
Study 22482874 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 222
Study 20494961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant approved dose (AD)
Number of subjects: 143
Study 20494961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant loading dose (LD)
Number of subjects: 143
Study 20494961 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant high dose (HD)
Number of subjects: 143
Study 18819457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicatridine
Number of subjects: 319
Study 15849476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal tinzaparin (4,500 anti-Xa IU)
Number of subjects: 21
Study 15849476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 21
Study 12373661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (TGB)
Number of subjects: 0
Study 10604492 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive glucose control
Number of subjects: 26
Study 11224347 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 or 50mg)
Number of subjects: 13
Study 11224347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5g/kg)
Number of subjects: 13
Study 11224347 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone pretreatment
Number of subjects: 13
Study 11224347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2198001 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conservation therapy
Number of subjects: 499
Study 2198001 — intervention group
Group type: COMPARATOR
Intervention: No locoregional recurrence
Number of subjects: 499
Study 2198001 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional recurrence
Number of subjects: 499
Study 1258750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (4.5 mg/kg)
Number of subjects: 46
Study 1258750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 31306396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam plus metronidazole
Number of subjects: 83
Study 31306396 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 83
Study 28718248 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% diltiazem cream
Number of subjects: 184
Study 28718248 — intervention group
Group type: COMPARATOR
Intervention: 0.2% glyceryl trinitrate cream
Number of subjects: 184
Study 25770048 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured presentation (S group)
Number of subjects: 105